

Principal Pharmaceuticals & Chemicals Ltd.
513, Palm Spring, Link Road, Malad West, Mumbai - 400 064
AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31st March, 2010

Rs. In lacs

Sr. No.		Unaudited		Audited	Audited
		3 Months ended on 31st March, 2010	3 Months ended on 31st March, 2009	Year ended 31st March, 2010	Year ended 31st March, 2009
1	Net Sales/Income from operations	4.22	4.21	17.21	38.21
2	Other Income	0.07	-	0.11	0.14
	Total Income	4.29	4.21	17.32	38.35
3	Total Expenditure				
a.	(Increase)/decrease in stock trade	-	-	-	-
b.	Consumption of raw materials / cost of sales	-	0.15	0.31	0.15
c.	Staff Cost	(0.33)	1.54	1.53	1.57
d.	Power & Fuel & Oil	-	-	-	-
e.	Job processing charges	-	-	-	-
f.	Internet Business Development Cost	-	-	-	0.03
g.	Other expenditure (including Prov for doubtful debts)	0.30	83.88	13.38	90.21
4	Interest	-	2.00	-	2.04
5	Depreciation & Amortisation	9.27	16.28	36.93	41.42
6	Profit (+)/Loss (-) before tax (1+2-3-4-5)	(4.95)	(99.64)	(34.83)	(97.07)
	Less :				
7	Provision for taxation				
	- Current Year Tax	-	-	-	-
	- Deferred Tax	-	-	-	-
	- Earlier Years Income Tax	-	-	-	-
	- Fringe Benefit Tax	-	0.07	-	0.10
8	Net Profit (+)/Loss (-) before extraordinary itmes(6-7)	(4.95)	(99.71)	(34.83)	(97.17)
	Extraordinary Items :				
9	Add/(Less) : Credits/(Debits) due to Restructured Liabilities	-	(21.82)	-	(21.82)
10	Balance Carried to the Balance Sheet	(4.95)	(121.53)	(34.83)	(118.99)
11	Paid-up equity share capital (Face value Rs 10/- each)	599.97	599.97	599.97	599.97
12	Reserve excluding revaluation reserves (Net of debit balance of Profit & Loss Account)			(664.59)	(629.77)
13	Basic & diluted EPS for the period, for the year to date & for the previous year (prior to extraordinary item)	(0.08)	(1.66)	(0.58)	(1.62)
14	Annualised	(0.33)	(6.65)	(0.58)	(1.62)
15	Aggregate of Non-Promoters' Shareholding				
	No. of shares (in lacs)	40.79	40.79	40.79	40.79
	Percentage of Shareholding	67.99%	67.99%	67.99%	67.99%
16	Promoters and Promoter Group Shareholding				
	a. Pledged /Encumbered				
	- No. of Shares (in lacs)	-	14.14	-	14.14
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	-	73.65%	-	73.65%
	- Percentage of Shares (as a % of total sharecapital of the company)	-	23.57%	-	23.57%
	b. Non - Encumbered				
	- No. of Shares (in lacs)	19.21	5.06	19.21	5.06
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	100%	26.35%	100%	26.35%
	- Percentage of Shares (as a % of total sharecapital of the company)	32.01%	8.43%	32.01%	8.43%

1 The company's total capital is invested in Pharmaceutical and Intermediate segment hence, total operations / results are of that segment only except small income from eCommerce activities, which is insignificant and has no capital employed- either fixed or working capital.

2 The Company was declared as "Sick Company" by the Board for Industrial & Financial Reconstruction u/s 3(1)(o) of Sick Industrial Companies (Special Provision) Act, 1985. An order to that effect was received by the company in October, 2005. According to the latest directives BIFR, the Company prepared and submitted rehabilitation scheme to the operating agency which is under consideration before the H'ble Board. The company has settled & paid all its dues to all its secured creditors.

3 BSE has not yet revoked the suspension order though the company has complied with all the provisions of the listing agreement and paid listing fee upto March, 2011.

4 There were no complaints pending at the beginning of 4th Quarter. Complaints received during 4th Quarter - NIL; Complaints solved during 4th Quarter - NIL ; Complaints pending at the end of 4th Quarter - NIL.

5 The above results have been reviewed and taken on record at the meeting of the Audit Committee and the Board of Directors held on 31st May, 2010.

By Order of the Board

Place : Mumbai
Dated : 31st May, 2010

Pradeep Malu
President & CEO